Financials in USD. Standardized financial statements.
A compact view of how Avenue Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.40M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $1.40M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $4.69M | $11.28M | $14.54M | $8.04M | $3.74M | $5.21M | $26.27M | $21.82M | $6.70M | $2.38M |
| Operating Income? | -$3.29M | -$11.28M | -$14.54M | -$8.04M | -$3.74M | -$5.21M | -$26.27M | -$21.82M | -$11.42M | -$2.38M |
| EBITDA? | -$3.29M | -$11.70M | $4.05M | -$2.44M | $7,000 | -$5.15M | -$25.91M | $0 | $0 | -$188,000 |
| Income Before Tax | -$2.95M | -$11.70M | -$10.49M | -$3.60M | -$3.73M | -$5.15M | -$25.91M | -$21.55M | -$12.26M | -$3.18M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$268,000 | $0 | $0 |
| Net Income? | -$2.91M | -$11.65M | -$10.38M | -$3.55M | -$3.73M | -$5.15M | -$25.91M | -$21.55M | -$12.26M | -$3.18M |
| EPS? | $-0.93 | $-0.90 | $-73.60 | $-121.91 | $-3.29 | $-4.65 | $-24.38 | $-31.17 | $-27.71 | $-5.39 |
| Diluted EPS? | $-0.93 | $-0.90 | $-73.48 | $-121.91 | $-3.29 | $-4.65 | $-24.38 | $-31.17 | $-27.71 | $-5.39 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality